Article info

Download PDFPDF

Original research
Tight control for Crohn’s disease with adalimumab-based treatment is cost-effective: an economic assessment of the CALM trial

Authors

  1. Correspondence to Dr Remo Panaccione, InflammatoryBowel Disease Unit, Division of Gastroenterology and Hepatology, Department ofMedicine, University of Calgary, 6D32 TRW Building 3280 Hospital Drive,Calgary, AB T2N 4N1, Canada ; rpanacci{at}ucalgary.ca
View Full Text

Citation

Panaccione R, Colombel J, Travis SPL, et al
Tight control for Crohn’s disease with adalimumab-based treatment is cost-effective: an economic assessment of the CALM trial

Publication history

  • Received January 10, 2019
  • Revised June 4, 2019
  • Accepted June 12, 2019
  • First published July 8, 2019.
Online issue publication 
March 06, 2020

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.